Objective To investigate the clinical effect of Regorafenib combined with programmed cell death receptor 1(PD-1) in the treatment of recurrent and metastatic colorectal cancer.Methods A total of 50 patients with recurrent and metastatic colorectal cancer (patients with advanced colorectal cancer who had received ≥2 lines of systemic therapy)admitted to the Department of Oncology,Xinyu People's Hospital from January to June 2022 were selected as the research objects.According to the random number table method,they were divided into observation group(25 cases)and control group(25 cases).The control group was treated with Regorafenib,and the observation group was treated with Regorafenib combined with Camrelizumab.The efficacy,carcinoembryonic antigen (CEA),carbohydrate antigen 72-4 (CA72-4),carbohydrate antigen 19-9 (CA19-9),endothelial growth factors (vascular endothelial growth factor [VEGF],matrix metalloproteinase 9 [MMP-9],epidermal growth factor receptor [EGFR],human epidermal growth factor receptor-2[HER-2]),and adverse reactions were compared between the two groups.Results There was no significant difference in response rate (RR)and disease control rate (DCR)between the two groups (P＞0.05).Before intervention,there were no statistically significant differences in the levels of CEA,CA72-4 and CA19-9 between the two groups (P＞0.05).After intervention,the levels of CEA,CA72-4 and CA19-9 of the two groups were lower than those before intervention,and the levels of CEA,CA72-4 and CA19-9 of the observation group were lower than those of the control group,and the differences were statistically significant (P＜0.05).Before intervention,there were no statistically significant differences in the levels of VEGF,MMP-9,EGFR and HER-2 between the two groups(P＞0.05).After the intervention,the levels of VEGF,MMP-9,EGFR and HER-2 in the two groups were lower than those before the intervention,and the levels of VEGF,MMP-9,EGFR and HER-2 in the observation group were lower than those in the control group,and the differences were statistically significant (P ＜0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant (P＜0.05).Conclusion Regorafenib combined with PD-1 preparation is effective in the treatment of recurrent and metastatic colorectal cancer,which can improve the levels of CEA,CA72-4,CA19-9 and endothelial growth factor,and does not increase the incidence of adverse reactions.